

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF FIRST SUBJECT ENROLLMENT IN PHASE II CLINICAL TRIAL OF AR-PROTAC(GT20029) FOR TREATMENT OF ANDROGENETIC ALOPECIA IN CHINA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that on 14 April 2023, the Company has completed the first subject enrollment in the phase II clinical trial (the “**Phase II Clinical Trial**”) in China of its proteolysis targeting chimera (“**PROTAC**”) compound GT20029 for the treatment of male androgenetic alopecia (“**AGA**”). GT20029 was developed based on the in-house PROTAC platform of the Company and is the first topical PROTAC compound which has entered the phase II clinical stage worldwide.

The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which was designed to evaluate the efficacy and safety of GT20029 for treating male AGA adults and determine the recommended dosage for phase III clinical trial in China. The primary endpoint of this trial is the change from baseline in non-vellus target area hair counts (TAHC) after 12 weeks of treatment in comparison to placebo. It plans to enroll a total of 180 subjects from 12 centers nationwide.

In November 2022 and February 2023, the Company respectively announced the positive top-line data for the phase I clinical trial of GT20029 for the treatment of AGA and acne in China (healthy subjects) and in the U.S. (healthy subjects and subjects with AGA or acne). The data demonstrated good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects or subjects with AGA or acne. For details, please refer to the announcements of the Company dated 24 November 2022 and 10 February 2023, respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 14 April 2023

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*